| Document |
Document Title |
|
WO/2022/120015A1 |
Therapeutic methods and pharmaceutical compositions for treating an ophthalmic condition including dry eye syndrome and uveitis in a human subject are described. In certain embodiments, the disclosure includes therapeutic methods using a...
|
|
WO/2022/120137A1 |
The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an ocular disease (e.g., glaucoma or age-related macular degeneration). The age-related macular degeneration may...
|
|
WO/2022/118271A1 |
The present invention provides an aqueous solution comprising difluprednate as the sole active ingredient, wherein the aqueous solution comprises 0.02% to 0.04% w/v difluprednate and an aqueous vehicle, wherein the aqueous solution is fr...
|
|
WO/2022/111379A1 |
An axitinib implant, comprising axitinib and a biodegradable polymer. The implant is stable and can achieve sustained release for at least six months, thus avoiding multiple repeated administrations, and reducing side effects. The prepar...
|
|
WO/2022/112957A1 |
The invention relates to methods for treating ocular disease with a VEGF antagonist. In particular, the invention relates to methods for treating ocular disease, e.g., neovascular age-related macular degeneration (nAMD), in a patient, th...
|
|
WO/2022/113887A1 |
A purpose of the present invention is to provide a novel assessment method that enables early detection, assessment of severity, and assessment of therapeutic effect, etc., of chronic inflammatory retinal diseases including age-related m...
|
|
WO/2022/114111A1 |
[Problem] To provide a composition that can mature or stabilize blood vessels. [Solution] This composition contains pentosan polysulfate and/or a salt thereof as an active ingredient, and is useful for treating and/or preventing diseases...
|
|
WO/2022/112511A1 |
The present invention relates to a pharmaceutical composition useful for the local administration onto the tympanic membrane and diffusion through the tympanic membrane without perforation of the membrane, for use in the treatment of an ...
|
|
WO/2022/110494A1 |
Provided are a method for reprogramming a cell in the presence of one or more reprogramming factors, a reprogrammed cell obtained by using the method and use thereof, and a kit comprising the reprogramming factors.
|
|
WO/2022/113970A1 |
Provided are a therapeutic agent for short tear breakup time (TBUT)–type dry eye, which has excellent therapeutic effect on dry eye and high safety, and eye drops containing the therapeutic agent. The present inventors found that a t...
|
|
WO/2022/107791A1 |
The present invention addresses the problem of exploring an additional combination of diquafosol and a preservative, said combination enabling the preparation of a clear diquafosol ophthalmic solution, while having sufficient preservativ...
|
|
WO/2022/107789A1 |
The present invention addresses the problem of searching for an easily handleable combination of diquafosol and an antiseptic agent when producing a clear diquafosol eye drop having sufficient preservation efficacy. The present inventi...
|
|
WO/2022/107735A1 |
The present invention addresses the problem of providing a novel crystalline lens hardness adjustment agent that can be easily, simply, and safely ingested over an extended period of time, and that can effectively adjust the hardness of ...
|
|
WO/2022/107790A1 |
The problem addressed by the present invention is that of searching for an easy-to-handle diquafosol/preservative combination for preparing a diquafosol ophthalmic solution that does not exhibit a change in formulation, is clear in color...
|
|
WO/2022/108334A1 |
An ophthalmic composition of the present invention comprises cetirizine, a pharmaceutically acceptable salt thereof, and/or an optical isomer thereof, as active ingredients, and comprises tocofersolan. Therefore, the ophthalmic compositi...
|
|
WO/2022/106523A1 |
The present invention discloses a non-aqueous gel composition which is useful for administration of pharmaceutically active agents, in particular for transtympanic administration of pharmaceutically active agents. The non-aqueous gel com...
|
|
WO/2022/107886A1 |
Eyedrops for ameliorating retinal circulatory disturbance and disorders associated with retinal nerve blood vessels, which contains fibrate-containing nanoparticles.
|
|
WO/2022/102713A1 |
This invention relates to novel salts and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-
1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol, simply abbreviated as Compound A, which is a selective CB2 re...
|
|
WO/2022/101377A1 |
Cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which ca...
|
|
WO/2022/099431A1 |
Provided are the crystalline solid meglumine salts of (R)-5-(4-chlorophenyl)-1-isopropyl-2-methyl-4-(3-(4-(4-((4-(
(1-(phenylthio)-4-(4- ((phosphonooxy)methyl)piperidin-1-yl)butan-2-yl)amino)-3-((t
rifluoromethyl)sulfonyl)phenyl)sulfonam...
|
|
WO/2022/101678A2 |
The present invention relates to formulations of lyso-phospholipids for use in medicine, in particular nasal formulations of lysophosphatidylcholine for treating, preventing and/or relieving one or more symptoms and/or signs of a 1) dise...
|
|
WO/2022/103250A1 |
Described is an ophthalmic composition for preventing, controlling and treating the symptoms of presbyopia, which comprises, in a low-concentration dose, a synergistic combination of pilocarpine, brimonidine, oxymetazoline, hyaluronic ac...
|
|
WO/2022/104383A1 |
Provided are compounds useful for treating, preventing, reducing the occurrence of, slowing the progression of, or reducing, ameliorating, or alleviating the symptoms associated with a condition selected from the group consisting of: pre...
|
|
WO/2022/101821A1 |
The present invention relates to a stable formulation based on polyhexamethylene biguanide (PHMB) suitable for administration at an ophthalmic level, a process for its preparation and relative dosage regimen effective for the treatment o...
|
|
WO/2022/097731A1 |
The objective of the present invention is to reduce the cellular cytotoxicity of an algefacient and/or strengthen the cooling sensation of the algefacient. It was discovered that the cellular toxicity of menthol, which is the algefacient...
|
|
WO/2022/097654A1 |
The present invention provides novel eyedrops containing tafluprost. The eyedrops comprise tafluprost and a biguanide- or alcohol-based antiseptic.
|
|
WO/2022/098121A1 |
Provided is a dispersion composition comprising: a dispersion medium; and particles comprising a target substance, wherein the dispersion composition includes at least one type of surfactant having a critical micelle concentration or hig...
|
|
WO/2022/095765A1 |
Disclosed in the present invention is the use of a P55PIK inhibitor in the preparation of a drug for treating dry eye disease.
|
|
WO/2022/098740A1 |
An antibacterial and /or antiviral treatment composition for optical components and method of application comprises a Quaternary Ammonium Compound (QAC) that contains a silicon moiety. The SiQAC is configured to covalently bond to an opt...
|
|
WO/2022/096965A1 |
The present invention refers to combinations, compositions and kits of parts comprising thymol, or at least an extract of plant belonging to the genus Thymus containing thymol, and tocopherol as well as to their use in the prevention and...
|
|
WO/2022/098080A1 |
The present invention relates to a novel anti-Tie2 antibody or an antigen-binding fragment thereof, and use thereof. The present invention provides an antibody or an antigen-binding fragment thereof, comprising: at least one heavy chain ...
|
|
WO/2022/097156A1 |
Ophthalmic formulations comprising a PARI antagonist and/or an agent that interferes with an interaction of PARI and a protease (e.g., thrombin), and an ophthalmically acceptable carrier, and uses thereof in treating or preventing retina...
|
|
WO/2022/096738A1 |
The present invention relates to new type II collagen alpha I chain specific binding proteins. The invention further refers to type II collagen binding proteins further fused to or conjugated to a therapeutically or diagnostically active...
|
|
WO/2022/099007A1 |
Described herein are variant adeno-associated virus (AAV) capsid polypeptides and gene therapeutics thereof for use in the treatment or prevention of hearing loss.
|
|
WO/2022/096702A1 |
The present invention relates to a storage-stable pharmaceutical composition for ophthalmic administration in the form of an aqueous solution comprising a therapeutically effective amount of antibiotic levofloxacin or a pharmaceutically ...
|
|
WO/2022/092326A1 |
The present invention provides a novel method for treating disorders in which ocular tissue fibrosis occur, by using a substance that inhibits the action of Growth Differentiation Factor 15 (GDF15).
|
|
WO/2022/090302A1 |
The invention provides methods, compositions, and kits containing a pharmaceutical composition, for treating meibomian gland dysfunction, dry eye disease, and related disorders.
|
|
WO/2022/092279A1 |
[Problem] To provide a pharmaceutical composition containing siRNA, as an active ingredient, that suppresses the BAZF expression. Specifically, the pharmaceutical composition is a prophylactic and/or therapeutic agent that, through suppr...
|
|
WO/2022/090379A1 |
The invention relates to the use of nitric oxide releasing cyclic guanosine 3',5' monophosphate (cGMP) phosphodiesterase type 5 inhibitors (NO-PDE5 inhibitors) in a method for the treatment of dry age-related macular degeneration and geo...
|
|
WO/2022/091995A1 |
[Problem] To provide a composition for a functional food. [Solution] A composition for a functional food that includes cis-astaxanthin.
|
|
WO/2022/092209A1 |
The present invention provides an ocular-tension-increasing agent containing a temperature-responsive polymer. By administering said ocular-tension-increasing agent to a specific region of an eye, the ocular tension thereof can be increa...
|
|
WO/2022/093652A1 |
Disclosed herein are pharmaceutical compositions comprising an azobenzene photoswitch compound and an alkylated cyclodextrin. Such compositions may be administered to the eye to treat a variety of retina disorders.
|
|
WO/2022/094364A1 |
The present invention relates to methods for treating a subject with risk factors for progression to iRORA, iRORA, nGA, cRORA, GA, AMD, intermediate AMD, dry AMD, and/or wet AMD, in a subject in need thereof comprising administration of ...
|
|
WO/2022/094340A1 |
The present disclosure relates to dosage regimens of complement factor H (CFH) protein for treating patients having inflammatory ocular diseases or conditions (e.g., age-related macular degeneration or early-onset macular dystrophies). T...
|
|
WO/2022/093818A1 |
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
|
|
WO/2022/090746A1 |
The present invention provides a NMT inhibitor for use in the prophylaxis or treatment of a senescence-associated disease or disorder.
|
|
WO/2022/094410A1 |
The present disclosure provides methods for generating retinal cell clusters for use in cellular component transfer therapy, retinal cell clusters generated by such methods, and compositions comprising such retinal cell clusters. The pre...
|
|
WO/2022/092896A1 |
The present invention relates to an ophthalmic therapeutic agent having a poorly soluble drug of chemical formula 1 as a pharmacologically active ingredient. Specifically, the ophthalmic solution formulation is administered to a patient ...
|
|
WO/2022/087669A1 |
Described herein are fusion peptides comprising (i) a peptide sequence comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:24 or a fragment or derivative thereof, or a sequence at least about 80% identical thereto and (ii) an ...
|
|
WO/2022/094106A1 |
Compositions and methods are described for the delivery of a fully human post-translationally modified therapeutic monoclonal antibody, or an antigen binding fragment thereof, that binds to TNF-α, IL6 or IL6-R to a human subject for tre...
|
